JP2021501581A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501581A5
JP2021501581A5 JP2020524267A JP2020524267A JP2021501581A5 JP 2021501581 A5 JP2021501581 A5 JP 2021501581A5 JP 2020524267 A JP2020524267 A JP 2020524267A JP 2020524267 A JP2020524267 A JP 2020524267A JP 2021501581 A5 JP2021501581 A5 JP 2021501581A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
polypeptide
gene locus
sequence encoding
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524267A
Other languages
English (en)
Japanese (ja)
Other versions
JP7397791B2 (ja
JP2021501581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058230 external-priority patent/WO2019089610A1/en
Publication of JP2021501581A publication Critical patent/JP2021501581A/ja
Publication of JP2021501581A5 publication Critical patent/JP2021501581A5/ja
Priority to JP2023150855A priority Critical patent/JP2024009805A/ja
Application granted granted Critical
Publication of JP7397791B2 publication Critical patent/JP7397791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524267A 2017-10-30 2018-10-30 初代細胞の遺伝子編集 Active JP7397791B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023150855A JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762579113P 2017-10-30 2017-10-30
US201762579114P 2017-10-30 2017-10-30
US62/579,113 2017-10-30
US62/579,114 2017-10-30
PCT/US2018/058230 WO2019089610A1 (en) 2017-10-30 2018-10-30 Primary cell gene editing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023150855A Division JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Publications (3)

Publication Number Publication Date
JP2021501581A JP2021501581A (ja) 2021-01-21
JP2021501581A5 true JP2021501581A5 (enExample) 2021-12-09
JP7397791B2 JP7397791B2 (ja) 2023-12-13

Family

ID=66332290

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524267A Active JP7397791B2 (ja) 2017-10-30 2018-10-30 初代細胞の遺伝子編集
JP2023150855A Pending JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023150855A Pending JP2024009805A (ja) 2017-10-30 2023-09-19 初代細胞の遺伝子編集

Country Status (13)

Country Link
US (7) US10550406B2 (enExample)
EP (1) EP3703712A4 (enExample)
JP (2) JP7397791B2 (enExample)
CN (2) CN117904055A (enExample)
AU (1) AU2018357861B2 (enExample)
BR (1) BR112020008704A2 (enExample)
CA (1) CA3081320A1 (enExample)
IL (1) IL274351B2 (enExample)
MX (1) MX2020004541A (enExample)
RU (1) RU2020116585A (enExample)
SG (1) SG11202004026QA (enExample)
TW (1) TWI716758B (enExample)
WO (1) WO2019089610A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) * 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
EP3703712A4 (en) * 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES
KR20200138334A (ko) 2018-04-02 2020-12-09 팩트 파마, 인크. 펩티드-MHC comPACT
CA3116132A1 (en) * 2018-10-16 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for immunotherapy
MX2021013218A (es) 2019-05-01 2021-12-10 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
AU2020325225A1 (en) * 2019-08-05 2022-03-24 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making
US12359247B2 (en) 2019-08-26 2025-07-15 Adoc Ssf, Llc Methods of performing GUIDE-Seq on primary human T cells
IL291935A (en) * 2019-10-08 2022-06-01 Pact Pharma Inc Methods for immunotherapy of genetically modified autologous t cells
EP4041293A1 (en) * 2019-10-10 2022-08-17 PACT Pharma, Inc. Method of treating immunotherapy non-responders with an autologous cell therapy
EP4110356A4 (en) * 2020-02-28 2024-03-27 Wisconsin Alumni Research Foundation NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING
AU2021261011A1 (en) * 2020-04-24 2022-11-10 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
WO2021252898A1 (en) * 2020-06-12 2021-12-16 Pact Pharma, Inc. Compositions and methods of manufacturing autologous t cell therapies
IL300994A (en) * 2020-08-28 2023-04-01 Arsenal Biosciences Inc Transgenic immune cells with priming receptors
TW202233830A (zh) * 2020-10-27 2022-09-01 美商Pact製藥公司 使用下一代工程化t細胞療法治療癌症之組合物及方法
WO2022204443A1 (en) * 2021-03-24 2022-09-29 Genentech, Inc. Efficient tcr gene editing in t lymphocytes
TW202309272A (zh) * 2021-03-24 2023-03-01 美商建南德克公司 T淋巴球中之高效tcr基因編輯
WO2022242644A1 (zh) * 2021-05-18 2022-11-24 赛斯尔擎生物技术(上海)有限公司 修饰细胞的方法
JP2024523014A (ja) 2021-06-11 2024-06-25 パクト ファーマ インコーポレイテッド 細胞製剤を査定する方法
US20260232734A1 (en) 2023-02-27 2026-08-13 Adaptive Biotechnologies Corporation Therapeutic T-Cell Receptors Targeting KRAS G12D

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
AU2014235968B2 (en) * 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
US20190030071A1 (en) * 2014-11-03 2019-01-31 IMMURES S.r.I. T cell receptors
ES2768984T3 (es) * 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
ES2803728T3 (es) * 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
US20190241910A1 (en) 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
SG11202003798TA (en) 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
EP3703712A4 (en) * 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES

Similar Documents

Publication Publication Date Title
CN105683215B (zh) 高稳定性的t细胞受体及其制法和应用
ES2848478T3 (es) Receptores quiméricos para antígenos y usos de estos
IL274200B1 (en) Methods, compositions, and implantable elements comprising active cells
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2018138049A5 (enExample)
RU2020116585A (ru) Редактирование гена первичных клеток
JP2017538401A5 (enExample)
EP2570429A3 (en) Peptide vaccines with Seq ID No: 48, 41, 44, 46 or 78 for cancers expressing tumor-associated antigens
UA120917C2 (uk) Химерний білок фактора viii та його застосування
WO2021198706A3 (en) Coronavirus vaccines
JP2017537622A5 (enExample)
JP2014500724A5 (enExample)
WO2012159006A8 (en) Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof
JP2014508510A5 (enExample)
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
JP2018509936A5 (enExample)
WO2017190684A1 (zh) 白细胞介素组合及其用途
JP2018502600A5 (enExample)
JP2017513502A5 (enExample)
JP2016503655A5 (enExample)
JP2019500414A5 (enExample)
US11932679B2 (en) Agent for restoring visual function or agent for preventing deterioration in visual function
RU2014135053A (ru) Иммуногены для вакцинации против вич
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда